Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Oracle Corp ( ORCL - Analyst Report ) has reportedly released a patch to fix a potential bug in the Java software for computers. Oracle released the software patch, “Update 11”, to plug the loophole in the Java system and upgrade the security level from medium to high.
The U.S. Department of Homeland Security had earlier warned users to refrain from using Java software in their computers unless absolutely necessary. The government body claimed that the applications running on Java’s latest version, Java 7, were vulnerable to hacking and could lead to cyber-crimes. However, users cannot do without Java, as disabling it would lead to blockage of real-time data display on websites.
Security experts believe that the Java software had always had its vulnerabilities and thus the new threat is not uncommon. According to Kaspersky Lab, Java was responsible for almost 50% of all the cyber attacks last year, while Adobe's ( ADBE - Analyst Report ) Acrobat Reader was responsible for 28% of the cyber attacks.
Nonetheless, Java remains the most widely-used programming language for any type of operating system, whether Microsoft's ( MSFT - Analyst Report ) Windows, Apple's ( AAPL - Analyst Report ) OS X or Linux. Oracle inherited Java through the acquisition of Sun Microsystems in 2010.
Moreover, Oracle enjoys a dominant position in the enterprise software and database management system market. Higher spending on enterprise IT will also positively impact the company. According to market research firm Gartner, worldwide enterprise IT spending is expected to increase 2.5% year over year to $2.68 trillion in 2013.
However, we believe that competition remains stiff for Oracle, limiting its growth prospects going forward. Oracle’s hardware business continues to decline, putting the onus on the software segment to perform consistently in order to drive growth.
Currently, Oracle has a Zacks Rank #2 (Buy).
Read the full reports :
Analyst Report on AAPL
Analyst Report on MSFT
Analyst Report on ORCL
Analyst Report on ADBE